



Announcement Summary

Entity name

PARADIGM BIOPHARMACEUTICALS LIMITED..

Announcement Type

New announcement

Date of this announcement

Wednesday June 17, 2026

The +securities to be quoted are:

Other

Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue.

Please refer to announced "Options Prospectus" <https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-03099444-3A695157&v=undefined>

Total number of +securities to be quoted

ASX +security code	Security description	Number of +securities to be quoted	Issue date
New class - code to be confirmed	Options expiring 1 December 2026 or 20 BD post IA announcement	117,069,101	15/06/2026

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

PARADIGM BIOPHARMACEUTICALS LIMITED..

We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.

1.2 Registered number type

ACN

Registration number

169346963

1.3 ASX issuer code

PAR

1.4 The announcement is

New announcement

1.5 Date of this announcement

17/6/2026



Part 2 - Type of Issue

2.1 The +securities to be quoted are:

Other

Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue.

2.2 The +class of +securities to be quoted is:

New +securities in a class that is not yet quoted on ASX ("new class")

2.3c Have these +securities been offered under a +disclosure document or +PDS?

Yes

2.3c.1 Date of +disclosure document or +PDS?

11/6/2026

2.3d Please provide any further information needed to understand the circumstances in which you are applying to have these +securities quoted on ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B

Please refer to announced "Options Prospectus" <https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-03099444-3A695157&v=undefined>



Part 3C - number and type of +securities to be quoted (new class) where issue has not previously been notified to ASX in an Appendix 3B

New +securities

ASX +security code

New class - code to be confirmed

+Security description

Options expiring 1 December 2026 or 20 BD post IA announcement

+Security type

Options

ISIN code

Issue date

15/6/2026

Will all the +securities issued in this class rank equally in all respects from the issue date?

Yes

Have you received confirmation from ASX that the terms of the +securities are appropriate and equitable under listing rule 6.1?

Yes

Distribution Schedule

Provide a distribution schedule for the new +securities according to the categories set out in the left hand column - including the number of recipients and the total percentage of the new +securities held by the recipients in each category.

Number of +securities held	Number of holders	Total percentage of +securities held For example, to enter a value of 50% please input as 50.00
1 - 1,000	0	0.00 %
1,001 - 5,000	11	0.04 %
5,001 - 10,000	16	0.12 %
10,001 - 100,000	384	11.34 %
100,001 and over	224	88.50 %

Options Details

+Security currency	Exercise price	Expiry date
AUD - Australian Dollar	AUD 0.23750000	1/12/2026



Details of the type of +security that will be issued if an option is exercised

PAR : ORDINARY FULLY PAID

Number of +securities that will be issued if an option is exercised

One Ordinary Fully Paid

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities to be quoted or provide the information by separate announcement.

<https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-03099444-3A695157&v=undefined>

Issue details

Number of +securities to be quoted

117,069,101

Are the +securities being issued for a cash consideration?

No

Please describe the consideration being provided for the +securities

N/A

Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted

0.000000

Any other information the entity wishes to provide about the +securities to be quoted

The purpose(s) for which the entity is issuing the securities

Other

Please provide additional details

For the Company's Phase III Clinical Trial activities



Part 4 - Issued capital following quotation

Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise:

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application)

ASX +security code and description	Total number of +securities on issue
PAR : ORDINARY FULLY PAID	576,499,282
New class - code to be confirmed : Options expiring 1 December 2026 or 20 BD post IA announcement	117,069,101

4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
PARAAC : PERFORMANCE RIGHTS	12,066,600
PARAR : OPTION EXPIRING 11-FEB-2028 EX \$1.00	151,293
PARAAE : OPTION EXPIRING 30-JUN-2027 EX \$0.65	3,000,000
PARAAD : CONVERTIBLE NOTES	6,297,185



Part 5 - Other Listing Rule requirements

5.1 Are the +securities being issued under an exception in Listing Rule 7.2 and therefore the issue does not need any security holder approval under Listing Rule 7.1?

No

5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?

Yes

5.2a Date of meeting or proposed meeting to approve the issue under listing rule 7.1

11/6/2026